Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer

NCT04289792 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neoplasms

Interventions

DRUG: nab-Paclitaxel+Gemcitabine
RADIATION: split-course SBRT

Sponsor

Fujian Medical University Union Hospital